Overview of receptor allosterism
- PMID: 21935895
- DOI: 10.1002/0471141755.ph0121s51
Overview of receptor allosterism
Abstract
In addition to the orthosteric site, which recognizes endogenous ligands, most G protein-coupled receptors (GPCRs) possess topographically distinct allosteric sites that can be recognized by small molecules and accessory cellular proteins. Ligand binding to allosteric sites promotes a conformational change in the GPCR that can alter orthosteric ligand affinity and/or efficacy. Moreover, there has been an increase in recent years in the identification of allosteric agonists that can directly activate the receptor in the absence of orthosteric ligand. Allosteric sites are attractive therapeutic targets because they can be exploited to achieve modes of selectivity and signaling that are not attainable by orthosteric means. However, an important challenge in this field remains the quantification of the myriad of possible allosteric effects on binding and signaling events. This unit provides an overview on GPCR allosterism and the different pharmacological approaches to understanding allosteric behaviors.
© 2010 by John Wiley & Sons, Inc.
Similar articles
-
G protein-coupled receptor allosterism and complexing.Pharmacol Rev. 2002 Jun;54(2):323-74. doi: 10.1124/pr.54.2.323. Pharmacol Rev. 2002. PMID: 12037145 Review.
-
When simple agonism is not enough: emerging modalities of GPCR ligands.Mol Cell Endocrinol. 2011 Jan 15;331(2):241-7. doi: 10.1016/j.mce.2010.07.009. Epub 2010 Jul 21. Mol Cell Endocrinol. 2011. PMID: 20654693 Review.
-
Strategies for the identification of allosteric modulators of G-protein-coupled receptors.Biochem Pharmacol. 2011 Mar 15;81(6):691-702. doi: 10.1016/j.bcp.2010.12.012. Epub 2010 Dec 22. Biochem Pharmacol. 2011. PMID: 21184747 Review.
-
Allosteric modulation of G protein-coupled receptors.Annu Rev Pharmacol Toxicol. 2007;47:1-51. doi: 10.1146/annurev.pharmtox.47.120505.105159. Annu Rev Pharmacol Toxicol. 2007. PMID: 17009927 Review.
-
Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.J Med Chem. 2017 May 25;60(10):4126-4134. doi: 10.1021/acs.jmedchem.6b01601. Epub 2017 Feb 15. J Med Chem. 2017. PMID: 28140580 Review.
Cited by
-
Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.Mol Pharmacol. 2012 Nov;82(5):860-75. doi: 10.1124/mol.112.080531. Epub 2012 Aug 3. Mol Pharmacol. 2012. PMID: 22863693 Free PMC article.
-
Novel GPCR paradigms at the μ-opioid receptor.Br J Pharmacol. 2015 Jan;172(2):287-96. doi: 10.1111/bph.12600. Epub 2014 Jul 1. Br J Pharmacol. 2015. PMID: 24460711 Free PMC article. Review.
-
Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.Neuropharmacology. 2017 Sep 15;124:3-12. doi: 10.1016/j.neuropharm.2017.05.018. Epub 2017 May 17. Neuropharmacology. 2017. PMID: 28527758 Free PMC article. Review.
-
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.Neuron. 2017 May 3;94(3):431-446. doi: 10.1016/j.neuron.2017.03.016. Neuron. 2017. PMID: 28472649 Free PMC article. Review.
-
Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators.ACS Pharmacol Transl Sci. 2024 Nov 5;7(12):3671-3690. doi: 10.1021/acsptsci.4c00213. eCollection 2024 Dec 13. ACS Pharmacol Transl Sci. 2024. PMID: 39698283 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources